Article
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2014
Hu Xingsheng, Han Baohui, Gu Aiqin, Zhang Yiping, Jiao Shun Chang, Wang Chang-Li, He Jintao, Jia Xueke, Zhang Li, Peng Jiewen, Wu Meina, Ying Kejing, Wang Junye, Ma Kewei, Zhang Shucai, You Changxuan, Tan Fenlai, Wang Yinxiang, Ding Lieming, Sun Yan
Abstract excerpt
BACKGROUND: The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients, and this led to the approval of icotinib for NSCLC by the China Food and Drug Administration. A phase 4 study was conducted to assess the safety and efficacy of icotinib in a broad range of patients with advanced NSCLC across...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.